https://orcid.org/0000-0001-8341-7300
References
- Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
- Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol. 2009;60:218–224.
- Takahashi H, Nakamura K, Kaneko F, et al. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002–2008. J Dermatol. 2011;38:1125–1129.
- Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
- van den Reek J, Kievit W, Gniadecki R, et al. Drug survival studies in dermatology: principles, purposes, and pitfalls. J Invest Dermatol. 2015;135:1–5.
- Mayba JN, Gooderham MJ. Real-world experience with apremilast in treating psoriasis. J Cutan Med Surg. 2017;21:145–151.
- Vujic I, Herman R, Sanlorenzo M, et al. Apremilast in psoriasis: a prospective real-world study. J Eur Acad Dermatol Venereol. 2018;32:254–259.
- Papadavid E, Rompoti N, Theodoropoulos K, et al. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018;32:1173–1179.
- Lee EB, Amin M, Wu JJ. Drug survival of apremilast for psoriasis in a real-world setting. J Am Acad Dermatol. 2018;79:760–761.